Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome

Ou, Huang-Tz; Chen, Pei-Chi; Wu, Meng-Hsing; Lin, Chung-Ying

doi:10.1186/s12955-016-0520-9

Health and Quality of Life Outcomes

Table 4 Mixed effect model analysis of metformin effect on PCOS-specific HRQoL measured via Chi-PCOSQ

From: Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome

Chi-PCOSQ	Total Coefficient (SE)	Subgroups
Chi-PCOSQ	Total Coefficient (SE)	Normal weight Coefficient (SE)	Overweight Coefficient (SE)	Non- hyperandrogenism Coefficient (SE)	Hyperandrogenism Coefficient (SE)
Total scores
Treatment time
Visit 2 (reference = visit 1)	0.44 (0.56)	0.75 (0.86)	0.20 (0.75)	−0.58 (0.89)	0.61 (0.66)
Visit 3 (reference = visit 1)	1.25 (0.56)	1.77 (0.84)	0.80 (0.78)	0.11 (0.92)	1.45 (0.66)*
Weight domain
Treatment time
Visit 2 (reference = visit 1)	−0.06 (0.14)	0.11 (0.22)	−0.18 (0.19)	−0.04 (0.28)	−0.07 (0.17)
Visit 3 (reference = visit 1)	0.12 (0.15)	0.15 (0.21)	0.10 (0.20)	−0.01 (0.29)	0.15 (0.17)
Infertility domain
Treatment time	p = 0.043				p = 0.048
Visit 2 (reference = visit 1)	0.25 (0.18)	0.34 (0.23)	0.15 (0.29)	−0.06 (0.33)	0.32 (0.21)
Visit 3 (reference = visit 1)	0.46 (0.18)*	0.34 (0.24)	0.59 (0.28)*	0.12 (0.34)	0.52 (0.21)*
Menstrual domain
Treatment time
Visit 2 (reference = visit 1)	0.10 (0.18)	0.21 (0.29)	0.02 (0.24)	0.26 (0.39)	0.08 (0.20)
Visit 3 (reference = visit 1)	0.19 (0.18)	0.36 (0.27)	0.04 (0.25)	0.58 (0.41)	0.11 (0.20)
Emotions domain
Treatment time
Visit 2 (reference = visit 1)	0.07 (0.15)	0.15 (0.21)	0.01 (0.21)	0.82 (0.33)*	0.04 (0.18)
Visit 3 (reference = visit 1)	0.14 (0.15)	0.30 (0.21)	0.003 (0.21)	0.43 (0.29)	0.13 (0.18)
Body hair domain
Treatment time
Visit 2 (reference = visit 1)	0.03 (0.14)	0.18 (0.19)	−0.08 (0.20)	−0.34 (0.20)	0.10 (0.17)
Visit 3 (reference = visit 1)	0.02 (0.14)	0.24 (0.18)	−0.16 (0.21)	−0.37 (0.21)	0.10 (0.17)
Acne & Hair loss domain
Treatment time	p = 0.008		p = 0.043		p = 0.007
Visit 2 (reference = visit 1)	−0.51 (0.28)	−0.10 (0.19)	0.01 (0.20)	−0.46 (0.18)*	−0.55 (0.35)
Visit 3 (reference = visit 1)	0.45 (0.26)	0.08 (0.19)	0.33 (0.21)	−0.28 (0.19)	0.71 (0.32)*

Note: Visit 1 is 1st office visit when patients were diagnosed with PCOS (baseline). Once PCOS was diagnosed, patients started metformin treatment. Visit 2 was 2nd office visit (1st-2nd month of treatment). Visit 3 was 3rd office visit (3rd- 4th month of treatment). The analysis was adjusted for the effect of medication adherence via the Morisky 8-item medication adherence scale
Abbreviations: PCOS polycystic ovary syndrome, HRQoL Health related Quality of life, SE standard error
*p < 0.05

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com